The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...

The company reported its second late-stage study success, this time with a drug that could become a new treatment standard ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...

Leaders and decision-makers facing the task of bringing new facilities online need construction partners who understand these ...